Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17218256
Ueki Y, et al. (2007) Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 128, 71-83 17218256
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (mouse)
Modsite: KDGATMKtFCGTPEY SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF increase
M-CSF SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF increase
M-CSF SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation

T203-p - ERK1 (mouse)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF increase
M-CSF SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation
RANKL, M-CSF increase
SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation

Y205-p - ERK1 (mouse)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF increase
M-CSF SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation
RANKL, M-CSF increase
SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation

T183-p - ERK2 (mouse)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF increase
M-CSF SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation
RANKL, M-CSF increase
SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation

Y185-p - ERK2 (mouse)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF increase
M-CSF SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation
RANKL, M-CSF increase
SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation

S32-p - IkB-alpha (mouse)
Modsite: LVDDRHDsGLDSMKD SwissProt Entrez-Gene
Orthologous residues
IkB‑alpha (human): S32‑p, IkB‑alpha (mouse): S32‑p, IkB‑alpha (rat): S32‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF no change compared to control
M-CSF SH3BP2 (mouse) increase homozygous P416R mutation

S36-p - IkB-alpha (mouse)
Modsite: RHDSGLDsMKDEEYE SwissProt Entrez-Gene
Orthologous residues
IkB‑alpha (human): S36‑p, IkB‑alpha (mouse): S36‑p, IkB‑alpha (rat): S36‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF no change compared to control
M-CSF SH3BP2 (mouse) increase homozygous P416R mutation

T180-p - P38A (mouse)
Modsite: RHTDDEMtGYVATRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF increase
M-CSF SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation

Y182-p - P38A (mouse)
Modsite: TDDEMTGyVATRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF increase
M-CSF SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation

S244-p - PDK1 (mouse)
Modsite: SKQARANsFVGTAQY SwissProt Entrez-Gene
Orthologous residues
PDK1 (human): S241‑p, PDK1 iso2 (human): S191‑p, PDK1 iso4 (human): S114‑p, PDK1 iso5 (human): S241‑p, PDK1 (mouse): S244‑p, PDK1 (rat): S244‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
M-CSF no change compared to control
M-CSF SH3BP2 (mouse) increase homozygous P416R mutation

Y317-p - Syk (mouse)
Modsite: STVSFNPyEPTGGPW SwissProt Entrez-Gene
Orthologous residues
Syk (human): Y323‑p, Syk iso2 (human): Y300‑p, Syk (mouse): Y317‑p, Syk (rat): Y317‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RANKL, M-CSF no change compared to control
M-CSF, RANKL SH3BP2 (mouse) no change compared to control homozygous P416R mutation

Y346-p - Syk (mouse)
Modsite: TEVYESPyADPEEIR SwissProt Entrez-Gene
Orthologous residues
Syk (human): Y352‑p, Syk iso2 (human): Y329‑p, Syk (mouse): Y346‑p, Syk (rat): Y346‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RANKL, M-CSF increase
SH3BP2 (mouse) augment treatment-induced increase homozygous P416R mutation

Y519-p - Syk (mouse)
Modsite: ALRADENyYKAQTHG SwissProt Entrez-Gene
Orthologous residues
Syk (human): Y525‑p, Syk iso2 (human): Y502‑p, Syk (mouse): Y519‑p, Syk (rat): Y519‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RANKL, M-CSF no change compared to control
M-CSF, RANKL SH3BP2 (mouse) no change compared to control homozygous P416R mutation

Y520-p - Syk (mouse)
Modsite: LRADENYyKAQTHGK SwissProt Entrez-Gene
Orthologous residues
Syk (human): Y526‑p, Syk iso2 (human): Y503‑p, Syk (mouse): Y520‑p, Syk (rat): Y520‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow, myeloid, osteoclast
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RANKL, M-CSF no change compared to control
M-CSF, RANKL SH3BP2 (mouse) no change compared to control homozygous P416R mutation